AMGEN TO PRESENT NEW DATA ACROSS RARE AND OTHER SERIOUS AUTOIMMUNE DISEASES AT ACR CONVERGENCE 2026
PR Newswire•27/10/2026•16:00 ET
0
Key Highlights
- ➤Dazodalibep Week 48 ESSDAI changes: −5.6 and −5.2 versus −3.8 for placebo
- ➤Dazodalibep every-four-weeks dryness score improved −2.50 versus −1.33 for placebo
- ➤UPLIZNA Phase 3 MITIGATE data will detail long-term safety and sustained efficacy in IgG4-RD
- ➤KRYSTEXXA and TAVNEOS evidence will add real-world data in uncontrolled gout and ANCA-associated vasculitis
Expert Statements
Teresa K. Tarrant, Associate Professor of Medicine, Duke University
“For patients living with Sjögren's disease, systemic disease activity and symptoms can have a significant impact on their health and daily lives, yet treatment options remain limited. The rapid improvements in ESSDAI, as well as self-reported dryness, observed with dazodalibep are particularly encouraging. These findings represent meaningful progress in our understanding of how we may be able to better manage both the systemic and symptomatic manifestations of this complex disease.”
Paul Burton, Senior Vice President and Chief Medical Officer at Amgen
“The data we're presenting at ACR demonstrate the breadth of Amgen's portfolio and pipeline across rare and other serious autoimmune diseases. By advancing investigational therapies, generating long-term clinical evidence and building on our understanding of medicines in real-world settings, we're working to address significant unmet needs for patients living with some of the most complex and serious diseases.”
AMGEN TO PRESENT NEW DATA ACROSS RARE AND OTHER SERIOUS AUTOIMMUNE DISEASES AT ACR CONVERGENCE 2026 PR Newswire
Phase 3 OASIZ-301 Study of Dazodalibep in Sjögren's Disease Shows Statistically Significant and Clinically Meaningful Improvement in Systemic Disease Activity and Patient-Reported Dryness
Get started
Create a free account to read the full story.